Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Imugene ( (AU:IMU) ) just unveiled an announcement.
Imugene Limited has announced the cessation of 175 IMUAAR convertible notes, which were cancelled by mutual agreement between the company and the noteholder effective 30 April 2026. The move slightly reduces Imugene’s issued capital in this class of securities and may simplify its balance sheet structure, with limited immediate operational impact but some relevance for investors tracking its capital management and financing arrangements.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian biotechnology company listed on the ASX under the ticker IMU. The company operates in the life sciences sector, focusing on the development of innovative therapies, with its capital structure including instruments such as convertible notes listed on the Australian Securities Exchange.
Average Trading Volume: 1,545,304
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$46.38M
See more data about IMU stock on TipRanks’ Stock Analysis page.